CJC-1295 (No DAC)
CJC-1295 Without DAC (10mg)
$80USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.219
Reference number
10mg
Lyophilized vial
Modified GHRH analog without Drug Affinity Complex. Produces a more pulsatile GH release pattern than the DAC version.
Origin
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of GHRH(1-29) with four amino acid substitutions to improve metabolic stability. It was developed by ConjuChem Biotechnologies in the early 2000s as part of their long-acting peptide platform.
Research Lineage
The modified GRF(1-29) analog was characterized by Jetté et al. at ConjuChem. The substitutions at positions 2, 8, 15, and 27 were shown to confer resistance to DPP-IV enzymatic degradation while preserving GHRH receptor binding. Without the DAC conjugation, the compound maintains a shorter half-life that produces discrete GH pulses.
Mechanism of Action
Like native GHRH, CJC-1295 without DAC activates the GHRH receptor on pituitary somatotrophs, stimulating GH release via cAMP/PKA signaling. The amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) prevent enzymatic cleavage at the DPP-IV site while maintaining receptor affinity. The absence of albumin conjugation results in a half-life of approximately 30 minutes, mimicking natural GHRH pulsatility.
Structural Notes
29-amino-acid modified peptide. Sequence modifications: D-Ala2, Gln8, Ala15, Leu27. Molecular weight: 3367.97 Da.
Key References
Jetté L et al. Endocrinology. 2005;146(7):3052-8.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.